Printer Friendly

Antimicrobial susceptibility and genetic characterisation of burkholderia pseudomallei isolated from malaysian patients.

1. Introduction

Melioidosis, an infectious disease of major public health importance, is a multifaceted disease which is difficult to treat and results in high morbidity and mortality. It is mostly endemic in Southeast Asia, Northern Australia, the Indian subcontinent, and Central and South America [1, 2]. The causative agent of this fatal disease, Burkholderia pseudomallei, is an environmental saprophyte that can be isolated from soil and water and is known as a potential biological warfare agent [2]. Infection of B. pseudomallei is acquired mainly through wound inoculation, inhalation, or ingestion [2, 3]. Melioidosis may arise many years after exposure, commonly in association with compromised immunity. Overall, the mortality rate of melioidosis is about 50% in Northeast Thailand (35% in children) [3] and 19% in Australia [4]. However, in Malaysia, it was associated with 65% mortality especially in the septicaemic form in the 1980s and reduced to 19-37% in the past 20 years [1,5-7]. Recurrence of infection is the most important complication in survivors despite prolonged antimicrobial treatment and this has been reported in 10% of Thai patients who survived the primary infection episode [4].

B. pseudomallei is intrinsically resistant to many antibiotics, including penicillin, first- and second-generation cephalosporins, macrolides, rifamycins, colistin, and aminoglycosides, but is usually susceptible to amoxicillin/clavulanic acid (AMC), chloramphenicol (CL), doxycycline (DOXY), trimethoprim/sulfamethoxazole (TS), ureidopenicillins, ceftazidime (CAZ), and carbapenems [8]. CAZ, AMC, or the carbapenem antibiotics are used for the initial parenteral phase of the therapy, followed by a prolonged course of oral antimicrobial therapy with either TS with or without DOXY or AMC [9]. However, CAZ-resistant (CAZR) and/or AMC-resistant B. pseudomallei have emerged, ultimately leading to treatment failure [9]. The carbapenems have been reported to have good bactericidal activities against B. pseudomallei and have been used effectively to treat patients with septicaemic melioidosis [10,11]. However, increased use of carbapenems may again give rise to resistance as observed with CAZ and AMC.

Owing to the difficulty in eradication of the organism following infection, prolonged antibiotic therapy is needed and a high rate of relapse was observed if the therapy is incomplete [12]. Furthermore, recurrence of infection is common despite adequate antimicrobial therapy [13]. It has been shown that B. pseudomallei isolated from relapse cases and persistent infections were resistant to antibiotics for treatment [3, 14].

Thus, the aim of this study was to investigate the antimicrobial susceptibility profile of B. pseudomallei against a panel of medically relevant antibiotics including CAZ, AMC, DOXY, and TS. Evaluation using other antimicrobials such as CL, meropenem (MERO), imipenem (IMP), tigecycline (TGC), and clarithromycin (CLA) were also included. The antimicrobial susceptibility was performed using two determination methods, that is, the agar disc diffusion and Etest. Additionally, polymerase chain reaction (PCR) technique utilising specific primers was also used for detection of antibioticsresistantgenesasthisprovestobereliablefor detection of [beta]-lactam, aminoglycosides, and CAZR genes in multidrug resistant (MDR) isolates. Further investigation using random amplification of polymorphic DNA (RAPD) analysis was performed to identify the genetic relationships among the isolates and the mode of dissemination of the antibiotic resistance genes.

2. Materials and Methods

2.1. Ethics Statement. Ethics approval is not required in this study. No consent was required since no human participant was involved. All 70 clinical B. pseudomallei isolates used in this study were obtained from old archival bacterial collection and all the isolates used were anonymised. Since our institute is a teaching hospital, bacterial isolates obtained as a part of a diagnostic screening are archived and such cases are exempted from obtaining ethical clearances. The study however has an Institutional Biosafety Committee approval.

2.1.1. Bacterial Strains. A total of 81 B. pseudomallei isolates (70 clinical, 10 animal, and 1 soil) and one Burkholderia thailandensis (ATCC 700388) isolates were investigated in this study. Of the 70 clinical B. pseudomallei, 60 isolates were obtained from archival collections of strains isolated at the Medical Microbiology Diagnostic Laboratory, University of Malaya Medical Centre (UMMC, Kuala Lumpur), and 10 from Hospital Tengku Ampuan Afzan (HTAA, Kuantan, Pahang). The ten animal isolates were kindly provided by S Nathan (Universiti Kebangsaan Malaysia), Malaysia, and the soil isolate was obtained from the Bacteriology Unit, Institute of Medical Research (IMR), Malaysia. These isolates were confirmed using Gram-stain, morphological appearance on Ashdown agar, molecular identification using an in-house PCR method [18] and standard biochemical characterisation using API 20NE assay (Bio-Merieux, France). Escherichia coli (ATCC 25922) was used as control while B. pseudomallei K96243 was used as reference strain. The isolates used in this study were obtained from different sources, that is, soil, animal and human (blood, pus, sputum, urine, spleen, and lungs).

2.2. Antibiotic Susceptibility Testing

2.2.1. Disk Diffusion Test. In vitro antimicrobial susceptibility to nine antibiotics/antimicrobials, namely, CL, AMC, DOXY, MERO, IMP, CAZ, TGC, CLA, and TS, was determined using disc diffusion method according to the British Society of Antimicrobial Chemotherapy [19]. Nutrient agar plates were seeded with 100 [micro]L of [10.sup.6] colony forming unit per milliliter (CFU/mL) of the test isolates, which had been adjusted to 0.5 McFarland reading spectrophotometrically at 600 nm. The agar plates were then incubated at 37[degrees]C for 24 hrs.

2.2.2. Minimum Inhibitory Concentrations (MICs). Antimicrobial MICs were determined using the broth dilution method and Etest. The broth dilution method was performed using Luria-Bertani (LB) broth (Difco, Lennox) for 24 hrs at 37[degrees]C with [10.sup.5] CFU/mL of B. pseudomallei (previously washed using normal saline) as the inoculum. Interpretation of the broth dilution results was based on the NCCLS MIC breakpoints for non-Enterobacteriaceae and MIC for B. pseudomallei and B. thailandensis [19]. Inhibition of the bacterial growth was confirmed by spectrophotometric measurement at 600 nm and plating of the serial dilutions onto LB agar. Wells containing bacteria without antibiotics and fresh LB broth were included as positive and negative growth controls, respectively. E. coli ATCC 25922 was used as quality control organism in the antimicrobial MIC determinations. MIC determination using Etest strips (AB Biodisk, Sweden) was performed according to the manufacturer's instruction.

2.2.3. Polymerase Chain Reaction (PCR). The DNA of all the isolates tested was extracted using Qiagen Mini Amp Kit (Qiagen, USA) according to the manufacturer's instruction. Primers (PenA-F and PenA-R) were used to identify the presence of penA gene from class A [beta]-lactamase which causes the CAZR (Table 1). Presence of the efflux pump, another main resistance mechanism, was also detected using the degenerate primers, MxBs, MxYs, and MxFs (Table 1). PCR amplification was performed in 25 [micro]L mixture containing 1X PCR buffer (MBI Fermentas, USA), 2mM Mg[Cl.sub.2], 0.2 mM dNTP (MBI Fermentas, USA), 2.5 U Taq DNA polymerase (MBI Fermentas, USA), and 2 [iL of DNA template. The PCR conditions used were as follows: initial denaturation at 95[degrees] C for 5 mins, 30 cycles of 95[degrees]C for 1min, 55[degrees]C for 30s and 72[degrees]C for 1min, followed by a final extension for 10mins at 72[degrees]C. The amplified PCR products were analysed using 1.5% agarose gel (Promega, USA) electrophoresis in 1X TBE buffer at 90 V for 1hr and visualised using 3 [micro]L SYBR safe (Life Technology, USA) staining under UV illumination. The limit of dilution was determined by subjecting the DNA of the targeted organisms to PCR after 10-fold serial dilution to produce DNA concentration ranging from 10 mg/mL to 10 fg/mL [17].

2.2.4. Genotypic Analysis Using Random Amplified Polymorphic DNA (RAPD)-PCR. The RAPD analysis was performed using primer 272 (Table 1) in order to determine the fingerprinting patterns of the B. pseudomallei isolates [20]. The RAPD-PCR mixture (25 [micro]l) consisted of 100 ng of genomic DNA, 0.5 [micro]M primer, 1.25 U of Taq polymerase (MBI Fermentas), 0.2 mM of dNTP (Fermentas, USA), 1X Taq buffer with KCl (pH8), and Mg[Cl.sub.2] (2mM). The cycling condition employed includes (i) 4 cycles with each cycle consisting of 5mins at 94[degrees]C, 5mins at 36[degrees]C and 5 mins at 72[degrees]C, and (ii) 30 cycles with each cycle consisting of 1 min at 94[degrees]C, 1 min at 36[degrees]C, and 2 mins at 72[degrees]C, followed by a final extension step at 72[degrees]C for 10 mins. The RAPD products (one-ninth of each reaction mixture) were then separated on a 1.5% agarose gels at 90 V/cm for 2 hrs using 1 X TBE as the running buffer. Molecular size standards (VC1Kb ladder) (Fermentas, USA) were also included on the gels. The fingerprints were compared visually followed by analysis using the Gel Compare IIV 4.0 software (Applied Maths, Kortrijk, Belgium).

3. Results

3.1. Antibiotic Sensitivity Testing

3.1.1. Disk Diffusion. The results indicated that, of the 81 B. pseudomallei isolates tested, six were found to be MDR (resistant to MERO, IMP, and CAZ). However, the remaining 75 isolates were resistant to at least one of the antimicrobial agents (non-MDR). The MDR isolates had susceptibility results that were distinct from other isolates tested (Table 2). The MERO- and IMP-resistant isolates had smaller inhibition zone (15.7 mm) compared to the sensitive isolates (20 to 25 mm). These isolates were also persistently mucoid and the inhibition zone diameter was not distinct. Among the 81 B. pseudomallei isolates, only 4.94% were CAZR and 2.47% showed intermediate susceptibility to CAZ, which is among the drug of choice for treatment of melioidosis. The CAZR isolates had no inhibition zone compared to the CAZ-sensitive isolates (24 to 29 mm).

3.1.2. MIC Etest. The highest reading for the Etest results (0.125-128 mg/L) was demonstrated for the MICs of CAZ, which also correlated with the most resistant isolate identified by disk diffusion (Tables 2 and 3). The Etest results also demonstrated that 100% of the CAZR isolates were shown to be resistant to MERO. The isolate with the highest measurable CAZ Etest result was also found to confer highest resistance towards MERO.

3.1.3. MIC Broth Microdilution. Conventional broth microdilution MIC results for CAZ, AMC, MERO, IMP, and TS were found to correlate with the Etest MIC results (Table 3). However, there was no significant correlation between MICs of MERO Etest and MICs determined by the disc diffusion and Etest.

3.1.4. PCR Amplification. PCR results demonstrated that the efflux pump genes (bpeB, amrB, and BPSS1119) and class A [beta]-lactams gene (penA) were present in all the six MDR isolates found in this study (Table 2, Figure 1). We also observed that isolates which showed the presence of penA also demonstrated the presence of bpeB, amrB, and BPSS1119.

3.1.5. Molecular Typing of Antibiotic-Resistant B. pseudomallei Strains Using RAPD. A total of six different PCR fingerprinting patterns were generated from the six MDR isolates. However, eight different PCR fingerprinting patterns were generated for the remaining 75 non-MDR isolates. Based on the differences in the banding patterns, a distinct cluster (A) was identified among the 6 MDR isolates which contain the bpeB, amrB, and BPSS1119 and penA genes, and among the 75 non-MDR isolates, only a single distinct cluster (B) was found (Table 2 and Figure 2).

4. Discussion

In the current scenario, melioidosis is considered as a fatal disease with no effective vaccine available. Treatmentalso requires prolonged and high dosage antibiotic therapy to accomplish complete eradication. Nevertheless, prolonged therapy can lead to the development of resistance and to make matters worse, the causative agent, B. pseudomallei, is intrinsically resistant to a wide range of antibiotics. Thus, treatment options for melioidosis are limited to a small number of antimicrobial agents such as CAZ (primary treatment) and TS, DOXY, or AMC (secondary treatment) [21]. Despite many trials, CAZ remains as the drug of choice for treatment of severe melioidosis [22]. Carbapanems have also been shown to be highly active against B. pseudomallei [23]. As a result, resistance developed towards these antibiotics can pose a significant challenge in treatment of melioidosis.

In our study, comparison of Etest and broth micro dilution against disk diffusion test for 81B. pseudomallei strains and a B. thailandensis strain showed broad range of MICs and zone inhibition, respectively. Our findings may also be indicative of the increased antibiotic resistance in B. pseudomallei clinical strains. In short, it appears that either disc diffusion or Etest could be applied for susceptibility testing in the case of CL, AMC, DOXY, MERO, IMP, CAZ, TGC, CLA, and TS in B. pseudomallei isolates (Table 2).

Additionally, in general, the Etest based antimicrobial susceptibility testing has the advantage of providing quantitative MICs results, which may be useful for clinicians to select appropriate treatments while the disc diffusion is a more reliable and cost effective technique for determining the prevalence of resistance among B. pseudomallei isolates in the more routine monitoring of melioidosis. A study by Piliouras et al., on the comparison of antibiotic susceptibility testing methods for TS with B. pseudomallei, also reported that the disc diffusion test was inappropriate for assessing the susceptibility of B. pseudomallei to TS. The study suggested that MIC based methods such as Etest may be a better choice for the determination of susceptibility for TS [24]. Difficulty in interpretation of disc diffusion results have also been implicated in previous studies which demonstrate varying susceptibility test results for TS with B. pseudomallei [25, 26]. This may be attributed to a few reasons including the imprecise endpoints for this combination of antimicrobial agent and organism as well as NCCLS guidelines being based on control standards of Pseudomonas aeruginosa and not B. pseudomallei [27, 28]. Thus, it is also evident that further creation of suitable internationally accepted MIC/zone inhibition breakpoints needs to be established through multilaboratory quality control. Several studies have been proposed for determination of the MICs, since these methods are cost effective and still able to produce reliable results [15, 29].

We also performed molecular level investigation to detect the presence of efflux pump and class A [beta]-lactamase genes, which were found to be present in all the MDR B. pseudomallei isolates. Previous studies have associated the mutations in class A [beta]-lactamase gene of B. pseudomallei to the resistance towards some cephalosporins and [beta]-lactamase inhibitors [15]. It has been previously demonstrated that mutations in the B. pseudomallei class A [beta]-lactamase coded by penA may confer resistance of the organism to CAZ. Both the low and high level of CAZR in the study of B. pseudomallei clinical isolates were confirmed by the detection of penA gene [15]. The presence of penA in B. pseudomallei used in our study matched the disc diffusion and MICs results.

Additionally, the necessity to characterise genes encoding for MDR efflux pump arises from the increased resistance of B. pseudomallei to a number of antibiotics. The presence of resistant nodulation division (RND) efflux pumps may contribute to the acquired resistance to fluoroquinolones and cross-resistant to unrelated antimicrobials [30]. This is not surprising as the efflux pumps can be associated with MDR isolates since they may be specific for one substrate or transport a wide range of antibiotics of multiple classes [31]. Primers MxBs, MxYs, and MxFs were used to amplify genes that encode proteins which are parts of the RND efflux pump [30]. The role of this efflux pump is associated with resistance towards a wide range of antibiotics including pefloxacin, ofloxacin, and CAZ in B. pseudomallei and accompanied by an increased resistance to aminoglycosides, [beta]-lactams, macrolides, and CL [30, 31]. In this study, isolates that contained these genes (bpeB, amrB, and BPSS1119) were shown to be resistant to AMC, CLA, and CAZ as reported using the disc diffusion and MICs. The bpeB, amrB, and BPSS1119 genes used in our study focus on chromosomally encoded MDR efflux pumps, which have been the best developed and the most widely used for demonstrated efflux pump genes using primers [31].

In conclusion, our study demonstrated the antimicrobial susceptibility profiles of B. pseudomallei against antibiotics that are commonly used for treatment including CAZ, AMC, DOXY, and TS as well as other antimicrobials such as CL, MERO, IMP, TGC, and CLA. The antimicrobial susceptibility profiles did not show any significant correlation with the origin of the isolates as similarly reported in a previous study [32]. We also highlighted that the CAZR is due to the presence of penA, bpeB, amrB, and BPSS1119 in B. pseudomallei. However, except for the six blood isolates, none of the animal, soil, sputum, pus, lung, or spleen isolates were tested positive with the PCR detection assays for penA, bpeB, amrB, and BPSS1119. Thus, it may be possible that the resistant blood isolates were from relapse patients or patients who did not comply with antibiotic treatment. However, this remains to be elucidated. Horizontal dissemination of these genes may contribute to further emergence of CAZR in various other Gram-negative bacteria. Therefore, appropriate surveillance and control measures are essential to prevent further spread of the CAZR organisms. Further study using PCR-single-stranded conformational polymorphism (PCR-SSCP) to identify the point mutations which take place in the B. pseudomallei isolates will be used to compliment and facilitate better understanding of the impact of CAZR in clinical practice.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


This study was supported by Ministry of Higher Education (MOHE), Malaysia, under the High Impact Research (HIR)-MOHE Project UM.C/625/1/HIR/060 (J-20004-73594).


[1] A. C.Cheng and B. J.Currie, "Melioidosis: epidemiology, pathophysiology, and management," Clinical Microbiology Reviews, vol. 18, no. 2, pp. 383-416, 2005.

[2] N. J. White, "Melioidosis," The Lancet, vol. 361, no. 9370, pp. 1715-1722, 2003.

[3] N. Mookherjee and R. E. W. Hancock, "Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections," Cellular and Molecular Life Sciences, vol. 64, no. 7-8, pp. 922-933, 2007.

[4] S. Kanthawong, K. Nazmi, S. Wongratanacheewin, J. G. M. Bolscher, V. Wuthiekanun, and S. Taweechaisupapong, "In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides," International Journal of Antimicrobial Agents, vol. 34, no. 4, pp. 309-314, 2009.

[5] S. D. Puthucheary, N. Parasakthi, and M. K. Lee, "Septicaemic melioidosis: a review of 50 cases fromMalaysia," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 86, no. 6, pp. 683-685, 1992.

[6] B. J. Currie, D. A. Fisher, D. M. Howard et al., "Endemic melioidosis in tropical northernAustralia: a 10-year prospective study and review of the literature," Clinical Infectious Diseases, vol. 31, no. 4, pp. 981-986, 2000.

[7] S. H. How, K. H. Ng, A. R. Jamalludin, A. Shah, and Y. Rathor, "Melioidosis in Pahang, Malaysia," Medical Journal of Malaysia, vol. 60, no. 5, pp. 606-613, 2005.

[8] C. D. Ciornei, A. Egesten, and M. Bodelsson, "Effects of human cathelicidin antimicrobial peptide LL-37 on lipopolysaccharide-induced nitric oxide release from rat aorta in vitro," Acta Anaesthesiologica Scandinavica, vol. 47, no. 2, pp. 213-220, 2003.

[9] R. Perumal Samy, A. Pachiappan, P. Gopalakrishnakone et al., "In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei," BMC Infectious Diseases, vol. 6, article 100, 2006.

[10] F. M. Thibault, E. Hernandez, D. R. Vidal, M. Girardet, and J. Cavallo, "Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents," Journal of Antimicrobial Chemotherapy, vol. 54, no. 6, pp. 1134-1138, 2004.

[11] S. A. Loutet, R. S. Flannagan, C. Kooi, P. A. Sokol, and M. A. Valvano, "A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo," Journal of Bacteriology, vol. 188, no. 6, pp. 2073-2080, 2006.

[12] K. Kawasaki, K. China, and M. Nishijima, "Release of the lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to the antimicrobial peptide polymyxin B in Salmonella enterica," Journal of Bacteriology, vol. 189, no. 13, pp. 4911-4919, 2007.

[13] S. Tandhavanant, A. Thanwisai, D. Limmathurotsakul et al., "Effect of colonymorphology variation of Burkholderia pseudomallei on intracellular survival and resistance to antimicrobial environments in human macrophages in vitro," BMC Microbiology, vol. 10, article 303, 2010.

[14] N. R. Lazar Adler, B. Govan, M. Cullinane, M. Harper, B. Adler, and J. D. Boyce, "The molecular and cellular basis of pathogenesis in melioidosis: how does Burkholderia pseudomallei cause disease?" FEMS Microbiology Reviews, vol. 33, no. 6, pp. 1079-1099, 2009.

[15] D. S. Sarovich, E. P. Price, A. T. von Schulze et al., "Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei fromAustralia," PLoS ONE, vol. 7, no. 2, Article ID e30789, 2012.

[16] D. V. Viktorov, I. B. Zakharova, M. V. Podshivalova et al., "High-level resistance to fluoroquinolones and cephalosporins in Burkholderia pseudomallei and closely related species," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 102, no. 1, pp. S103-S110, 2008.

[17] Y. Khosravi, S. Tee Tay, and J. Vadivelu, "Metallo-[beta]-lactamase-producing imipenem-resistant Pseudomonas aeruginosa clinical isolates in a university teaching hospital in Malaysia: detection of IMP-7 and first identification of IMP-4, VIM-2, and VIM-11," Diagnostic Microbiology and Infectious Disease, vol. 67, no. 3, pp. 294-296, 2010.

[18] J. Suppiah, J. S. Thimma, S. H. Cheah, and J. Vadivelu, "Development and evaluation of polymerase chain reaction assay to detect Burkholderia genus and to differentiate the species in clinical specimens," FEMSMicrobiology Letters, vol. 306, pp. 9-14, 2010.

[19] T. J. Inglis, F. Rodrigues, P. Rigby, R. Norton, and B. J. Currie, "Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods," Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2999-3005, 2004.

[20] Y. Khosravi, S. T. Tay, and J. Vadivelu, "Analysis of integrons and associated gene cassettes of metallo-[beta]-lactamase-positive Pseudomonas aeruginosa in Malaysia," Journal of Medical Microbiology, vol. 60, no. 7, pp. 988-994, 2011.

[21] A. Kumar, M. Mayo, L. A. Trunck, A. C. Cheng, B. J. Currie, and H. P. Schweizer, "Expression of resistance-nodulation-cell-division efflux pumps in commonly used Burkholderia pseudomallei strains and clinical isolates from northern Australia," Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 102, supplement 1, pp. S145-S151, 2008.

[22] A. J. H. Simpson, Y. Suputtamongkol, M. D. Smith et al., "Comparison of imipenem and ceftazidime as therapy for severe melioidosis," Clinical Infectious Diseases, vol. 29, no. 2, pp. 381-387, 1999.

[23] A. C. Cheng, D. A. Fisher, N. M. Anstey, D. P. Stephens, S. P. Jacups, and B. J. Currie, "Outcomes of patients with melioidosis treated with meropenem," Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1763-1765, 2004.

[24] P. Piliouras, G. C. Ulett, C. Ashhurst-Smith, R. G. Hirst, and R. E. Norton, "A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei," International Journal of Antimicrobial Agents, vol. 19, no. 5, pp. 427-429, 2002.

[25] J. Seymour-Murray, R. Norton, and C. Ashhurst-Smith, "Comparative in vitro susceptibility of Burkholderia pseudomallei to cefpirome, ceftazidime and cefepime," Pathology, vol. 29, no. 3, pp. 329-330, 1997.

[26] R.W. Guard, F. A. Khafagi, M. C. Brigden, and L. R. Ashdown, "Melioidosis in far North Queensland: a clinical and epidemiological review of twenty cases," The American Journal of Tropical Medicine and Hygiene, vol. 33, no. 3, pp. 467-473, 1984.

[27] W. Chaowagul, A. J. H. Simpson, Y. Suputtamongkol, M. D. Smith, B. J. Angus, and N. J. White, "A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis," Clinical Infectious Diseases, vol. 29, no. 2, pp. 375-380, 1999.

[28] D. A. B. Dance, V. Wuthiekanun, W. Chaowagul, and N. J. White, "The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment," Journal of Antimicrobial Chemotherapy, vol. 24, no. 3, pp. 295-309, 1989.

[29] L. J. V. Piddock, "Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria," Clinical Microbiology Reviews, vol. 19, no. 2, pp. 382-402, 2006.

[30] F.V. Biot, E.Valade, E. Garnotel et al., "Involvement of the efflux pumps in chloramphenicol selected strains of Burkholderia thailandensis: proteomic and mechanistic evidence," PLoSONE, vol. 6, no. 2, Article ID e16892, 2011.

[31] J. Turnidge and D. L. Paterson, "Setting and revising antibacterial susceptibility breakpoints," ClinicalMicrobiology Reviews, vol. 20, no. 3, pp. 391-408, 2007.

[32] G. C. Ulett, B. J. Currie, T. W. Clair et al., "Burkholderia pseudomallei virulence: definition, stability and association with clonality," Microbes and Infection, vol. 3, no. 8, pp. 621-631, 2001.

Yalda Khosravi, Kumutha Malar Vellasamy, Vanitha Mariappan, Shet-Lee Ng, and Jamuna Vadivelu

Tropical Infectious Disease Research and Education Center (TIDREC), Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia

Correspondence should be addressed to Jamuna Vadivelu;

Received 27 February 2014; Accepted 19 July 2014; Published 14 October 2014

Academic Editor: Glen C. Ulett

TABLE 1: Primers used in this study.

Name      Target                  Sequence                 Reference

MxBs-F     bpeB           5' GATCTCCGCGCAGAACGT3'            [16]
MxBs-R                    5' AGGCCGATCGCGAGCACG3'
MxYs-F     amrB           5' TTCATGCAGAACTTCCGC3'            [16]
MxYs-R                    5' GAACGCCATCGGCACGAA3'
MxFs-F   BPSS1119         5' CGTCGTGATTTTCCTGTT3'            [16]
MxFs-R                    5' ACGCGAACTCCTTGAACA3'
272      Variable             5' AGCGGGCCAA3'                [17]

TABLE 2: Origin, resistogram (disk diffusion), and RAPD of 81B.
pseudomallei isolates and a B. thailandensis isolate.

StrainID       Origin
           of isolation


Bp1        Blood    I
Bp2        Blood    I
Bp3        Blood    I
Bp4        Blood    S
Bp5        Blood    R
Bp6        Blood    S
Bp7        Blood    I
Bp8        Blood    S
Bp9        Blood    R
Bp10       Blood    S
Bp11       Urine    S
Bp12       Blood    I
Bp13       Blood    S
Bp14       Blood    S
Bp15       Blood    S
Bp16       Sputum   I
Bp17       Blood    I
Bp18        Pus     R
Bp19       Blood    I
Bp20       Blood    S
Bp21       Blood    I
Bp22       Blood    S
Bp23       Blood    I
Bp24        Lung    S
Bp25       Blood    I
Bp26       Blood    S
Bp27       Blood    S
Bp28       Blood    S
Bp29       Blood    I
Bp30       Spleen   I
Bp31       Blood    S
Bp32       Blood    I
Bp33       Blood    I
Bp34       Blood    S
Bp35       Blood    R
Bp36       Blood    S
Bp37       Blood    R
Bp38       Blood    I
Bp39       Blood    S
Bp40       Blood    S
Bp41       Sputum   I
Bp42       Blood    I
Bp43       Blood    I
Bp44       Blood    I
Bp45       Blood    I
Bp46       Blood    I
Bp47       Blood    S
Bp48       Blood    I
Bp49       Blood    S
Bp50       Blood    I
Bp51       Blood    S
Bp52       Blood    R
Bp53       Blood    I
Bp54       Blood    I
Bp55       Blood    R
Bp56       Blood    I
Bp57        Pus     I
Bp58       Sputum   S
Bp59       Sputum   S
Bp60       Sputum   S
Bp61       Animal   S
Bp62       Animal   I
Bp63       Animal   S
Bp64       Animal   S
Bp65       Animal   I
Bp66       Animal   I
Bp67       Animal   S
Bp68       Animal   I
Bp69       Animal   I
Bp70       Animal   I
Bt71        Soil    I
Bp72       Blood    I
Bp73       Blood    R
Bp74       Blood    I
Bp75       Blood    S
Bp77       Blood    R
Bp78       Blood    R
Bp79       Blood    R
Bp80       Blood    R
Bp81       Blood    I
Bp82        Soil    I

StrainID        Antimicrobial susceptibility testing

           CLA   DOXY   IMP   MERO   TGC   TS   CAZ   AMC

Bp1         S     S      S     S      R    S     S     S
Bp2         I     S      S     S      R    S     S     S
Bp3         I     R      R     S      R    S     S     I
Bp4         I     S      S     S      R    S     S     R
Bp5         R     R      R     R      R    R     R     R
Bp6         S     S      S     S      R    S     S     I
Bp7         S     S      S     S      R    S     S     R
Bp8         S     S      S     S      I    S     S     S
Bp9         R     S      S     S      R    S     S     R
Bp10        S     S      S     S      R    S     S     R
Bp11        S     S      S     S      R    S     S     R
Bp12        S     S      S     S      S    S     S     I
Bp13        S     S      S     S      S    S     S     I
Bp14        S     S      S     S      S    S     S     S
Bp15        I     S      S     S      S    S     S     I
Bp16        I     S      S     S      R    S     S     I
Bp17        S     S      S     S      R    S     S     I
Bp18        I     R      R     R      R    R     R     R
Bp19        I     S      S     S      R    S     S     S
Bp20        I     S      S     S      R    S     S     I
Bp21        S     S      S     S      R    R     S     R
Bp22        S     S      S     S      R    R     S     S
Bp23        I     S      S     S      R    I     S     I
Bp24        S     S      S     S      R    I     S     I
Bp25        R     R      R     R      R    R     I     R
Bp26        S     S      S     S      S    S     S     I
Bp27        S     S      S     S      S    R     S     I
Bp28        I     S      S     S      S    I     S     I
Bp29        S     S      S     S      S    R     S     I
Bp30        S     S      S     S      S    S     S     I
Bp31        S     S      S     S      R    R     S     I
Bp32        I     S      S     S      R    I     S     R
Bp33        I     S      S     S      S    R     S     I
Bp34        I     S      S     S      S    I     S     S
Bp35        R     R      R     R      S    R     I     S
Bp36        S     S      S     S      S    S     S     S
Bp37        I     R      R     R      R    R     R     I
Bp38        I     S      S     S      R    I     S     S
Bp39        S     S      S     S      R    S     S     S
Bp40        S     S      S     S      R    S     S     S
Bp41        S     S      S     S      R    S     S     R
Bp42        I     S      S     S      S    I     S     I
Bp43        I     S      S     S      S    S     S     I
Bp44        I     S      S     S      S    S     S     I
Bp45        I     S      S     S      S    S     S     S
Bp46        R     S      S     S      S    S     S     I
Bp47        S     S      S     S      R    I     S     R
Bp48        R     S      S     S      S    S     S     I
Bp49        I     S      S     S      R    S     S     R
Bp50        I     S      S     S      R    I     S     R
Bp51        S     S      S     S      R    I     S     R
Bp52        R     S      S     S      R    S     S     R
Bp53        R     S      S     S      R    I     S     I
Bp54        R     S      S     S      S    S     S     R
Bp55        S     S      S     S      S    I     S     I
Bp56        I     S      S     S      S    I     S     R
Bp57        R     S      S     S      S    I     S     R
Bp58        S     S      S     S      S    R     S     R
Bp59        I     S      S     S      R    I     S     I
Bp60        S     S      R     R      R    R     S     R
Bp61        I     S      S     S      S    I     S     S
Bp62        S     S      S     S      I    I     S     R
Bp63        S     S      S     S      S    I     S     R
Bp64        S     S      S     S      S    S     S     S
Bp65        S     S      S     S      I    S     S     R
Bp66        S     S      S     S      I    S     S     S
Bp67        S     S      S     S      S    S     S     I
Bp68        S     S      S     S      R    S     S     R
Bp69        S     S      S     S      S    S     S     S
Bp70        S     S      S     S      I    S     S     S
Bt71        I     S      S     S      R    I     S     R
Bp72        I     S      S     S      R    S     S     R
Bp73        I     S      S     S      R    S     S     R
Bp74        R     S      S     S      R    I     S     R
Bp75        S     S      S     S      S    S     S     S
Bp77        R     S      S     S      R    S     S     S
Bp78        I     S      S     S      I    S     S     S
Bp79        R     I      S     S      R    I     R     R
Bp80        R     I      S     S      R    I     S     I
Bp81        S     S      S     S      R    S     S     I
Bp82        S     S      S     S      R    S     S     R

StrainID   PCR detection

           PenA, bpeB, amrB & BPSS1119    RAPD

Bp1                  Negative              B
Bp2                  Negative              B
Bp3                  Negative              B
Bp4                  Negative              B
Bp5        PenA, bpeB, amrB & BPSS1119     A
Bp6                  Negative              B
Bp7                  Negative              B
Bp8                  Negative              B
Bp9                  Negative              B
Bp10                 Negative              B
Bp11                 Negative              B
Bp12                 Negative              B
Bp13                 Negative              B
Bp14                 Negative              B
Bp15                 Negative              B
Bp16                 Negative              B
Bp17                 Negative              B
Bp18       PenA, bpeB, amrB & BPSS1119     A
Bp19                 Negative              B
Bp20                 Negative              B
Bp21                 Negative              B
Bp22                 Negative              B
Bp23                 Negative              B
Bp24                 Ngative               B
Bp25       PenA, bpeB, amrB & BPSS1119     A
Bp26                 Negative              B
Bp27                 Negative              B
Bp28                 Negative              B
Bp29                 Negative              B
Bp30                 Negative              B
Bp31                 Negative              B
Bp32                 Negative              B
Bp33                 Negative              B
Bp34                 Negative              B
Bp35       PenA, bpeB, amrB & BPSS1119     A
Bp36                 Negative              B
Bp37        PenA, bpeB, amrB,&BPSS1119     A
Bp38                 Negative              B
Bp39                 Negative              B
Bp40                 Negative              B
Bp41                 Negative              B
Bp42                 Negative              B
Bp43                 Negative              B
Bp44                 Negative              B
Bp45                 Negative              B
Bp46                 Negative              B
Bp47                 Negative              B
Bp48                 Negative              B
Bp49                 Negative              B
Bp50                 Negative              B
Bp51                 Negative              B
Bp52                 Negative              B
Bp53                 Negative              B
Bp54                 Negative              B
Bp55                 Negative              B
Bp56                 Negative              B
Bp57                 Negative              B
Bp58                 Negative              B
Bp59                 Negative              B
Bp60                 Negative              B
Bp61                 Negative              B
Bp62                 Negative              B
Bp63                 Negative              B
Bp64                 Negative              B
Bp65                 Negative              B
Bp66                 Negative              B
Bp67                 Negative              B
Bp68                 Negative              B
Bp69                 Negative              B
Bp70                 Negative              B
Bt71                 Negative              B
Bp72                 Negative              B
Bp73                 Negative              B
Bp74                 Negative              B
Bp75                 Negative              B
Bp77                 Negative              B
Bp78                 Negative              B
Bp79       PenA, bpeB, amrB & BPSS1119     A
Bp80                 Negative              B
Bp81                 Negative              B
Bp82                 Negative              B

Foot note: R: resistant; I: intermediate; S: sensitive; CL:
chloramphenicol; AMC: amoxiclin/clavulanic acid; DOXY: doxycycline;
MERO: meropenem; IMP: imipenem; CAZ: ceftazidime; TGC: tigecycline;
CLA: clarithromycin; TS: trimethoprim/sulfamethoxazole. Intermediate
is counted as resistant.

(a) Blood, pus, sputum, urine, spleen, and lungs are of human origin.
Bp: B. pseudomallei; Bt: B. thailandensis.

TABLE 3: Broth microdilution and Etest MICs of 81 B. pseudomallei

                                      MIC (mg/L)

                                    Broth dilution

Antimicrobial agent             Range   50%    90%

Chloramphenicol                 4-16     8     16
Amoxiclin/clavulanic acid        4-8     8      8
Doxycycline                     0.5-1   0.5     1
Meropenem                        3-4     2    4 (a)
Imipenem                        0.5-1   0.5   1 (a)
Ceftazidime                     2-64     2    4 (a)
Tigecycline                      3-4     2      6
Clarithromycin                  4-16     4     16
Trimethoprim/sulfamethoxazole   4-64    16     64

                                          MIC (mg/L)


Antimicrobial agent               Range       50%     90%

Chloramphenicol                  0.25-24       3       8
Amoxiclin/clavulanic acid        0.125-2     0.25    0.25
Doxycycline                      0.19-16     0.19     16
Meropenem                          1-4         1      1.5
Imipenem                         0.094-8     0.094   0.125
Ceftazidime                     0.125-128    0.250    0.5
Tigecycline                       0.5-32       3       6
Clarithromycin                    1.5-48       1      32
Trimethoprim/sulfamethoxazole   0.003-0.25   0.032   0.125

Foot note: (a) multidrug resistant isolates.
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Khosravi, Yalda; Vellasamy, Kumutha Malar; Mariappan, Vanitha; Ng, Shet-Lee; Vadivelu, Jamuna
Publication:The Scientific World Journal
Article Type:Report
Geographic Code:9MALA
Date:Jan 1, 2014
Previous Article:Canine fecal contamination in a metropolitan area (Milan, North-Western Italy): prevalence of intestinal parasites and evaluation of health risks.
Next Article:Cytomictic anomalous male meiosis and 2n pollen grain formation in Mertensia echioides Benth.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |